



## Luncheon Seminar 3

# The Asian Pacific Association for the Study of the Liver (APASL) Oncology 2026 TOKYO

“Treatment Dynamics of liver Tumors”

2026

04.03

Friday

12:00  
13:00

Room 1

【Ito Hall B2F Ito International Research Center】  
(Hongo Campus, The University of Tokyo)  
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan

Theme :

## Five-Year Experience of Atezolizumab plus Bevacizumab for HCC: Clinical Insights and Future Strategies

Moderator

**Masafumi Ikeda MD. PhD.**

Deputy Director, National Cancer Center Hospital East, Chief, Department of Hepatobiliary and Pancreatic Oncology,  
Director, Supportive Care Center, National Cancer Center Hospital East, Japan

## Optimizing Atezolizumab-Bevacizumab Therapy for HCC : Real-World Evidence from 5-Year Multicenter Analysis of 1,200 Cases

12:00~12:30

Speaker

**Joji Tani M.D., Ph.D.**

Department of Comprehensive Community Medicine Kagawa University, Japan  
Faculty of Medicine : Specially appointed professor

## How to Optimize Atezolizumab plus Bevacizumab for Real-World HCC : Sequencing, Early Biomarkers, and On-Demand Add-On TACE

12:30~13:00

Speaker

**Teiji Kuzuya, MD., Ph.D.**

Professor, Department of Gastroenterology and Hepatology, Fujita Health University, Japan

Co-Sponsored by:

The Asian Pacific Association for the Study of the Liver (APASL) Oncology 2026 TOKYO  
/Chugai Pharmaceutical Co., Ltd